Meeting
2015 ASCO Annual Meeting
Prognostic value of BRAFV600 mutations in American Joint Committee on Cancer (AJCC) stage 3 cutaneous melanoma patients in the MelanCohort prospective cohort.
Authors
Philippe Saiag
Hospital Ambroise Pare, Boulogne-Billancourt, France
Philippe Saiag , Philippe Aegerter , Celeste Lebbe , Pierre Wolkenstein , Nicolas Dupin , Vincent Descamps , Selim Aractingi , Maxime Battistella , Zofia Helias-Rodzewicz , Samia Mourah , Jean-François Emile
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT00839410
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9037)
DOI
10.1200/jco.2015.33.15_suppl.9037
Abstract #
9037
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD.
First Author: Dirk Schadendorf
Poster
2023 ASCO Annual Meeting
Prognostic significance of immune-related adverse events and immunosuppression in patients with melanoma receiving adjuvant anti-PD-1 therapy.
First Author: Andrew David Knight
Poster
2022 ASCO Annual Meeting
Prognostic significance of the CP-GEP assay combining clinicopathologic factors and gene expression profiling in patients (pts) with AJCC v8 stage I/II cutaneous melanoma (CM).
First Author: Teresa Maria Santos Amaral
Poster
2020 ASCO Virtual Scientific Program
Effect of ARMS-qPCR on detection sensitivity of earlier diagnosis of papillary thyroid cancers with worse prognosis determined by BRAF V600E and TERT promoter mutation coexisting.
First Author: Peng-cheng Yu